Article

Daily Medication Pearl: Delafloxacin (Baxdela)

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Medication Pearl of the Day: Delafloxacin (Baxdela)

Indication: Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Insight:

  • Dosing: Administer delafloxacin for injection 300 mg by intravenous (IV) infusion over 60 minutes, every 12 hours, or a 450-mg delafloxacin tablet orally every 12 hours for 5 to 14 days total duration.
  • Dosage forms: For Injection 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single dose vial for reconstitution and further dilution before IV infusion.
  • Adverse events: Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.
  • Mechanism of action: Delafloxacin is an antibacterial drug.
  • Manufacturer: Melinta Therapeutics

Reference

BAXDELA (delafloxacin) Label (fda.gov)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com